Market open
aTyr Pharma/$ATYR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About aTyr Pharma
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Ticker
$ATYR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
58
Website
aTyr Pharma Metrics
BasicAdvanced
$321M
-
-$0.93
1.10
-
Price and volume
Market cap
$321M
Beta
1.1
52-week high
$4.66
52-week low
$1.42
Average daily volume
1M
Financial strength
Current ratio
5.406
Quick ratio
4.804
Long term debt to equity
18.973
Total debt to equity
20.832
Management effectiveness
Return on assets (TTM)
-39.26%
Return on equity (TTM)
-78.14%
Valuation
Price to revenue (TTM)
1,114.993
Price to book
4.44
Price to tangible book (TTM)
4.44
Price to free cash flow (TTM)
-3.904
Growth
Revenue change (TTM)
-97.81%
Earnings per share change (TTM)
-0.72%
3-year revenue growth (CAGR)
-51.45%
3-year earnings per share growth (CAGR)
-22.92%
What the Analysts think about aTyr Pharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for aTyr Pharma stock.
aTyr Pharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
aTyr Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
aTyr Pharma News
AllArticlesVideos
aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
GlobeNewsWire·4 weeks ago
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
GlobeNewsWire·2 months ago
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for aTyr Pharma stock?
aTyr Pharma (ATYR) has a market cap of $321M as of February 25, 2025.
What is the P/E ratio for aTyr Pharma stock?
The price to earnings (P/E) ratio for aTyr Pharma (ATYR) stock is 0 as of February 25, 2025.
Does aTyr Pharma stock pay dividends?
No, aTyr Pharma (ATYR) stock does not pay dividends to its shareholders as of February 25, 2025.
When is the next aTyr Pharma dividend payment date?
aTyr Pharma (ATYR) stock does not pay dividends to its shareholders.
What is the beta indicator for aTyr Pharma?
aTyr Pharma (ATYR) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.